364 related articles for article (PubMed ID: 31721133)
1. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy.
Bednarczuk T; Schomburg L
Hormones (Athens); 2020 Mar; 19(1):31-39. PubMed ID: 31721133
[TBL] [Abstract][Full Text] [Related]
2. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.
Watt T; Cramon P; Bjorner JB; Bonnema SJ; Feldt-Rasmussen U; Gluud C; Gram J; Hansen JL; Hegedüs L; Knudsen N; Bach-Mortensen P; Nolsøe R; Nygaard B; Pociot F; Skoog M; Winkel P; Rasmussen AK
Trials; 2013 Apr; 14():119. PubMed ID: 23782950
[TBL] [Abstract][Full Text] [Related]
3. Is selenium supplementation in autoimmune thyroid diseases justified?
Winther KH; Bonnema SJ; Hegedüs L
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):348-355. PubMed ID: 28639965
[TBL] [Abstract][Full Text] [Related]
4. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
5. Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease.
Lanzolla G; Marinò M; Marcocci C
Front Endocrinol (Lausanne); 2020; 11():608428. PubMed ID: 33574798
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy.
Marinò M; Dottore GR; Leo M; Marcocci C
Horm Metab Res; 2018 Dec; 50(12):887-893. PubMed ID: 30096720
[TBL] [Abstract][Full Text] [Related]
7. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
[TBL] [Abstract][Full Text] [Related]
8. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
[TBL] [Abstract][Full Text] [Related]
9. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
10. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
Bartalena L
J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
[TBL] [Abstract][Full Text] [Related]
11. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy.
Elbers L; Mourits M; Wiersinga W
Thyroid; 2011 Mar; 21(3):279-83. PubMed ID: 21190446
[TBL] [Abstract][Full Text] [Related]
12. Advances in the pharmacological treatment of Graves' orbitopathy.
Ruchała M; Sawicka-Gutaj N
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):981-9. PubMed ID: 26966785
[TBL] [Abstract][Full Text] [Related]
13. A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy.
Negro R; Hegedüs L; Attanasio R; Papini E; Winther KH
Eur Thyroid J; 2019 Jan; 8(1):7-15. PubMed ID: 30800636
[TBL] [Abstract][Full Text] [Related]
14. Selenium supplementation in inactive moderate to severe Graves' orbitopathy patients: a randomized controlled trial.
Potita P; Pruksakorn V; Srichomkwun P; Kingpetch K; Saonanon P
Orbit; 2024 Jun; 43(3):329-336. PubMed ID: 38374579
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
[No Abstract] [Full Text] [Related]
16. Efficacy of selenium supplementation for mild-to-moderate Graves' ophthalmopathy in a selenium-sufficient area (SeGOSS trial): study protocol for a phase III, multicenter, open-label, randomized, controlled intervention trial.
Chung CW; Jung KY; Jung EH; Lee MJ; Park YJ; Lee JK; Ahn HY; Cho SW
Trials; 2023 Apr; 24(1):272. PubMed ID: 37060084
[TBL] [Abstract][Full Text] [Related]
17. Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study.
Wang C; Qiao J; Liu S; Piao S; Zhou Y; Hu Y; Wan C; Sun Y; Ning H; Chen L; Zhang H; Hu R; Wang H; Wang W; Zhao L; Mao J; Li M; Teng W; Shan Z; Li Y
Endocrine; 2024 Jun; 84(3):1072-1080. PubMed ID: 38200401
[TBL] [Abstract][Full Text] [Related]
18. Effect of Selenium Supplementation on Recurrent Hyperthyroidism Caused by Graves' Disease: A Prospective Pilot Study.
Wang L; Wang B; Chen SR; Hou X; Wang XF; Zhao SH; Song JQ; Wang YG
Horm Metab Res; 2016 Sep; 48(9):559-64. PubMed ID: 27392116
[TBL] [Abstract][Full Text] [Related]
19. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
20. Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement.
Bartalena L; Macchia PE; Marcocci C; Salvi M; Vermiglio F
J Endocrinol Invest; 2015 Apr; 38(4):481-7. PubMed ID: 25722226
[No Abstract] [Full Text] [Related]
[Next] [New Search]
